Skip to main content

Lucira Health Higher as At-Home COVID Test Is Sold on Amazon

Lucira Health's 30-minute at-home COVID test received emergency-use authorization from the FDA. The stock is higher.
  • Author:
  • Publish date:

Shares of Lucira Health  (LHDX) - Get Lucira Health Inc. Report jumped Wednesday after the medical device maker said its at-home COVID-19 test would be available for sale on Amazon.  (AMZN) - Get Inc. Report 

The Lucira Check It test kit provides a PCR-quality test result at home in 30 minutes or less. Test takers can also receive a free verified test result via text on their phone for work or travel. 

The kit is "the first at-home COVID-19 self-test to provide an on-the-spot result with molecular accuracy available to millions of U.S. customers on Amazon," Chief Executive Erik Engelson said in a statement. 

Lucira shares at last check were up 18% to $6.01. 

Scroll to Continue

TheStreet Recommends

The Emeryville, Calif., company focuses on developing and commercializing test kits for infectious diseases. 

The Check It test kit is available over the counter in the U.S. The test costs $55 on Amazon's site.

Lucira's prescription version was the first prescription molecular diagnostic test for COVID-19 given emergency-use authorization by the U.S. Food and Drug Administration that could be self-administered by consumers at home or used in a doctor's office, the company said. 

Earlier this month, Precipio  (PRPO) - Get Precipio Inc. Report said it launched its own COVID-19 rapid antibody test on Amazon's business platform. 

The 20-minute antibody test, which is made by Nirmidas Biotech of Palo Alto, Calif., was the first U.S.-based test to receive emergency use authorization by the U.S. Food and Drug Administration for point-of-care, the company said in a statement.